Jonestrading began coverage on shares of Achieve Life Sciences (NASDAQ:ACHV – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. The firm issued a buy rating and a $20.00 price target on the biopharmaceutical company’s stock.
ACHV has been the subject of several other research reports. Lake Street Capital decreased their price objective on Achieve Life Sciences from $19.00 to $11.00 and set a buy rating for the company in a research note on Tuesday, March 5th. Oppenheimer restated an outperform rating and set a $18.00 target price on shares of Achieve Life Sciences in a research note on Monday, April 1st.
Get Our Latest Stock Report on ACHV
Achieve Life Sciences Stock Performance
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its holdings in shares of Achieve Life Sciences by 75.6% in the first quarter. Tower Research Capital LLC TRC now owns 3,646 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 1,570 shares during the period. HRT Financial LP purchased a new stake in shares of Achieve Life Sciences in the fourth quarter valued at approximately $32,000. Morgan Stanley boosted its stake in shares of Achieve Life Sciences by 437.4% in the fourth quarter. Morgan Stanley now owns 13,547 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 11,026 shares in the last quarter. Madison Park Capital Advisors LLC purchased a new stake in shares of Achieve Life Sciences in the fourth quarter valued at approximately $41,000. Finally, Prelude Capital Management LLC purchased a new stake in shares of Achieve Life Sciences in the second quarter valued at approximately $49,000. Institutional investors and hedge funds own 33.52% of the company’s stock.
About Achieve Life Sciences
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
See Also
- Five stocks we like better than Achieve Life Sciences
- How to Calculate Return on Investment (ROI)
- United Airlines Soars on Earnings Beat
- What Are Dividend Challengers?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.